[Comparative analysis of metastatic variants from the XXXX cell line HT-29]

@entity2289 @entity13959 @entity5 @entity787 @entity14 @entity3 @entity35 @entity2290
OBJECTIVE: To analyze the relationship between metastatic potential and related facters of @entity14 cell lines. METHODS: The variants HT-29c and HT-29d cell lines derived from the selection of HT-29 cells were injected into nude @entity35 and the metastatic potential of the two @entity5 cell variants was analyzed. Expression of @entity2290 ( @entity2290 ) and @entity2289 ( @entity2289 ) were measured with ELISA in vitro in @entity14 cell lines WiDr, HT-29 and HT-29d. Expression of @entity787 ( @entity787 ) and phosphoinositide 3-kinase ( @entity13959 -Kinase) were determined with immunohistochemistry, (IHC) in vitro and in vivo in WiDr, HT-29 and HT-29d cell lines. In addition, @entity787 expression was demonstrated with fluorescence activated cell sorter (FACS) in vitro. RESULTS: The liver @entity3 rate of the variant HT-29d (with 4 cycles of selection), increased as compared with that of parental HT-29 cells and that of variant HT-29b cells (with 2 cycle of selection). The @entity2290 concentration of variant HT-29d cell line was significantly higher than that of the non metastatic WiDr and the low metastatic HT-29 cells (P<0.05). The variant HT-29d cells produced stronger @entity13959 -kinase expression as compared with the non-anetastatic WiDr cells and the low metastatic HT-29 cells in vivo. CONCLUSION: The selected variant cell lines can exhibit an enhanced metastatic potential. The level of @entity2290 and @entity2289 are positively correlated with the metastatic capacity of @entity5 cells. The expression of @entity13959 kinasecorrelates with @entity5 development and @entity3 .
